DDInter927 DDInter786
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the HIV-1 viral lifecycle. The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically orthogonal therapies) for the treatment of HIV-1 patients with resistant infections. Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant HIV-1 infection whom are failing their current therapy.[L14867,L14917] Targeting gp120 subunits is a new and novel therapeutic approach to HIV-1 infection, and the addition of attachment inhibitors, like temsavir, to the armament of therapies targeted against HIV-1 fills a necessary niche for therapeutic options in patients left with few, if any, viable treatments.
Fostemsavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aminoglutethimide
Fostemsavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Fostemsavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinine
Fostemsavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Fostemsavir {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Fostemsavir {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide
Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Fostemsavir may lead to a major life threatening interaction when taken with Ribociclib
Fostemsavir may lead to a major life threatening interaction when taken with Macimorelin